Page last updated: 2024-09-05

sorafenib and imatinib

sorafenib has been researched along with imatinib in 29 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(imatinib)
Trials
(imatinib)
Recent Studies (post-2010) (imatinib)
6,5207305,2512360157

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)imatinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABLMus musculus (house mouse)0.1
Aurora kinase AHomo sapiens (human)4.3
Solute carrier family 22 member 2Homo sapiens (human)4.2
Bile salt export pumpHomo sapiens (human)10
Tyrosine-protein kinase ABL1Homo sapiens (human)0.6804
Tyrosine-protein kinase ABL1Mus musculus (house mouse)0.3704
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)2.784
Epidermal growth factor receptorHomo sapiens (human)0.0001
Carbonic anhydrase 2Homo sapiens (human)0.372
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0001
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.3
Tyrosine-protein kinase LckHomo sapiens (human)0.2667
Cyclin-dependent kinase 1Homo sapiens (human)4.3
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.8417
Tyrosine-protein kinase LynHomo sapiens (human)0.22
ATP-dependent translocase ABCB1Homo sapiens (human)5.0229
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.4
Hepatocyte growth factor receptorHomo sapiens (human)0.0216
Platelet-derived growth factor receptor betaHomo sapiens (human)0.285
Dihydrofolate reductaseEscherichia coli K-120.372
Mast/stem cell growth factor receptor KitHomo sapiens (human)1.2682
Breakpoint cluster region proteinHomo sapiens (human)0.5032
Solute carrier family 2, facilitated glucose transporter member 4Mus musculus (house mouse)0.473
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)5
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)0.175
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.1516
Thromboxane-A synthase Homo sapiens (human)0.198
Cyclin-dependent kinase 2Homo sapiens (human)3.318
Histamine H2 receptorHomo sapiens (human)1.963
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)0.3
5-hydroxytryptamine receptor 2AHomo sapiens (human)1.891
Sodium-dependent serotonin transporterHomo sapiens (human)1.402
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.131
Tyrosine-protein kinase ABL2Homo sapiens (human)0.156
Tyrosine-protein kinase SYKHomo sapiens (human)5
Serine/threonine-protein kinase PLK1Homo sapiens (human)4.3
Platelet-derived growth factor receptor betaRattus norvegicus (Norway rat)0.162
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.2964
Discoidin domain-containing receptor 2Homo sapiens (human)0.457
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)8.3
Multidrug and toxin extrusion protein 2Homo sapiens (human)1.625
Multidrug and toxin extrusion protein 1Homo sapiens (human)0.1467
Aurora kinase BHomo sapiens (human)4.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2.9096
Aurora kinase CHomo sapiens (human)4.3

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (20.69)29.6817
2010's17 (58.62)24.3611
2020's6 (20.69)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Knight, ZA; Shokat, KM1
Gray, NS; Liu, Y1
Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW1
Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Morphy, R1
Dietrich, J; Hulme, C; Hurley, LH1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Dubey, PK; Pal, M; Piedrafita, FJ; Rajitha, C; Sunku, V; Veeramaneni, VR1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, Y; Gao, D; Jiang, Y; Jin, F; Liu, F; Tan, C; Wu, Q1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y1
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB1
Ding, K; Li, Y; Lu, X; Ren, X1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bestgen, B; Borjini, N; Chevé, G; Daydé-Cazals, B; Fauvel, B; Feneyrolles, C; Gassiot, F; Singer, M; Spenlinhauer, A; Van Hijfte, N; Warnault, P; Yasri, A1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Cao, DS; Chen, AF; Chen, XS; Cheng, Y; Guan, YD; Jiang, SL; Yang, JM; Zhang, LX; Zhang, Y1
Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM1
Gong, YP; He, ZX; Ma, LY; Zhang, X; Zhao, W1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Laufer, S; Pillaiyar, T1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1

Reviews

9 review(s) available for sorafenib and imatinib

ArticleYear
Features of selective kinase inhibitors.
    Chemistry & biology, 2005, Volume: 12, Issue:6

    Topics: Animals; Drug Evaluation, Preclinical; Humans; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Substrate Specificity

2005
Selectively nonselective kinase inhibition: striking the right balance.
    Journal of medicinal chemistry, 2010, Feb-25, Volume: 53, Issue:4

    Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Humans; Protein Binding; Protein Kinase Inhibitors; Structure-Activity Relationship

2010
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
    Journal of medicinal chemistry, 2015, Apr-23, Volume: 58, Issue:8

    Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries

2015
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors

2021
Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Protein Binding; Protein Conformation; Proto-Oncogene Proteins c-met; Pyridazines; Pyrophosphatases; Structure-Activity Relationship

2021
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication

2022
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Other Studies

20 other study(ies) available for sorafenib and imatinib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
Rational design of inhibitors that bind to inactive kinase conformations.
    Nature chemical biology, 2006, Volume: 2, Issue:7

    Topics: Binding Sites; Drug Design; Humans; Models, Molecular; Phosphotransferases; Protein Kinase Inhibitors; Protein Structure, Tertiary

2006
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Biochemistry, 2007, Aug-21, Volume: 46, Issue:33

    Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin

2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-11, Volume: 104, Issue:50

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Bioorganic & medicinal chemistry, 2010, Aug-01, Volume: 18, Issue:15

    Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Drug Design; Hydrogen Bonding; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Naphthalenes; Niacinamide; Oligopeptides; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Oxazines; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
    ACS chemical biology, 2012, Jul-20, Volume: 7, Issue:7

    Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
    Bioorganic & medicinal chemistry, 2013, Sep-15, Volume: 21, Issue:18

    Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Imatinib Mesylate; K562 Cells; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Niacinamide; Piperazines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; Pyrrolidines; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2

2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index

2014
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Journal of medicinal chemistry, 2014, Oct-09, Volume: 57, Issue:19

    Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship

2014
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
    Journal of medicinal chemistry, 2016, 04-28, Volume: 59, Issue:8

    Topics: Animals; Cell Proliferation; Drug Design; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Male; Mice; Patch-Clamp Techniques; Protein Kinase Inhibitors

2016
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone.
    European journal of medicinal chemistry, 2020, Aug-01, Volume: 199

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epothilones; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Tumor Cells, Cultured

2020